Surgeons in Sports Medicine have been searching for a faster, better, and less invasive approach to ACL reconstruction for some time. The Biorez platform may well prove to be the world’s first synthetic ACL graft that fully remodels into new functional tissue.
New Haven, Conn. November 29, 2017
Biorez, Inc. announced today the establishment of a Scientific Advisory Board (SAB) composed of renowned academics, surgeons, clinical studies experts, and leaders in sports medicine and medical device development.
Biorez’s novel approach makes use of a proprietary tissue-engineered scaffold that stabilizes the knee, encourages regeneration of new ACL tissue, and then fully resorbs leaving only new, functional tissue. The company is currently conducting its second round of preclinical animal studies to demonstrate the safety and potential efficacy of the technology and gain regulatory approvals for human clinical study.
“We are extremely pleased to announce the formalization of our relationship with these distinguished individuals, each of whom already contributed significantly to the ongoing development of our technology,” said Kevin Rocco, Biorez CEO said. “This team has the diverse depth of expertise needed to reinvent ACL reconstruction, and we are grateful for their support and guidance.”
The five inaugural members of the Scientific Advisory Board are:
Robert A. Arciero, M. D., Professor and Chief of the Sports Medicine Division of the Department of Orthopaedic at the University of Connecticut Health Center. Dr. Arciero served as President of the American Orthopaedic Society of Sports Medicine in 2014-2015 and is a recipient of the prestigious George Rovere Award for his contributions in education.
Steven Arnoczky, DVM, DACVS, DACVSMR, Professor Emeritus, Small Animal Clinical Sciences Laboratory for Comparative Orthopedics Research at the College of Veterinary Medicine at Michigan State University. Dr. Arnoczky was the first Wade O. Brinker Endowed Professor of Surgery at Michigan State and, in recognition of his lasting contributions to sports medicine, was inducted into the American Orthopaedic Society for Sports Medicine's Hall of Fame (AOSSM) in 2014. He is the second non-physician to receive this honor.
Dale R. Peterson, Ph. D., Chief Science Officer at HemaFlo Therapeutics, Inc., of San Diego, CA. Dr. Peterson has commercialized 19 medical products and holds 24 U.S. patents in a variety of fields, including stem cells, new resorbable polymers, protein chemistry, growth factors, medical textiles, diagnostics, cell biology, and new biocompatible adhesives. He has helped launch more than a half dozen startups and joint ventures, including CellPro, DRP Biomedical, and Stericell.
Robert A. Stanton, M. D., served as President of the American Orthopaedic Society for Sports Medicine 2011-2012 and is currently Clinical Instructor of Orthopaedic Surgery at Yale University School of Medicine. Dr. Stanton maintains a private practice in Fairfield, CT while serving as Senior Attending Physician at Bridgeport Hospital and as staff at St. Vincent’s Medical Center and Fairfield Surgery Center.
Bill Walsh, Ph. D., Professor and Director of the Surgical & Orthopaedic Research Laboratories at the Prince of Wales Clinical School of the University of South Wales, Sydney, Australia. Dr. Walsh’s groundbreaking research focuses on the interface between implanted materials and the connective tissues of the body as it relates to orthopaedic, plastic and reconstructive and vascular surgery. In addition to serving on many university, government, and professional committees in the U.S. and Australia, he has published more than 300 peer-reviewed journal publications, book chapters, and patents.
With the announcement, Dr. Arnoczky said, “I am very excited to join the Biorez team. The company has made considerable progress with its technology over the past few years, and I look forward to helping guide the future development of this promising technology.”
Dr. Stanton added, “Surgeons in Sports Medicine have been searching for a faster, better, and less invasive approach to ACL reconstruction for some time. The Biorez platform may well prove to be the world’s first synthetic ACL graft that fully remodels into new functional tissue.”
About Biorez, Inc.
Biorez, Inc. is a privately held early-stage regenerative medicine company engaged in developing bioresorbable scaffold implants to regenerate functional tissue in vivo. Current R&D is focused on a bioresorbable polymer scaffold for ACL reconstruction that spares harvesting of patient donor-tissue (autograft), and provides a more attractive alternative to cadaver (allograft) and xenograft (animal) options. The company plans to commercialize its novel ACL technology and expand its platform to develop new and innovative clinical solutions. To learn more, please visit http://www.biorez.com.
Powered by WPeMatico